Prognostic impact of PTEN status in recurrent IDH-wildtype glioblastoma receiving second-line therapy

Clicks: 23
ID: 322649
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 145 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 145 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Recurrent IDH-wildtype glioblastoma has a poor prognosis, and no validated molecular biomarker guides second-line treatment choices. Because PTEN alterations are frequent in glioblastoma and may influence therapy resistance, we assessed their association with outcomes in patients with recurrence of IDH-wildtype glioblastoma. Methods This is a retrospective study including consecutive adults with first recurrence of IDH-wildtype glioblastoma treated between 2019 and 2022 with regorafenib, nitrosoureas, or bevacizumab. PTEN alterations were assessed by NGS. Overall survival was analyzed using Kaplan-Meier estimates and multivariable Cox models adjusted for clinically relevant covariates. An exploratory weighted analysis compared regorafenib and nitrosoureas in PTEN wild-type tumors. Results Among 226 patients, 128 (57%) had PTEN alterations. The prevalence was higher in patients who received regorafenib (66%) than in those treated with nitrosourea (48%) or bevacizumab (55%). In univariate analyses, PTEN alteration was associated with shorter survival with regorafenib (median OS, 9.4 vs 17.0 months; HR, 2.04; P = .043) and nitrosoureas (6.9 vs 8.0 months; HR, 1.63; P = .027), but not with bevacizumab (HR, 1.23; P = .60). In multivariable analyses, PTEN alteration remained associated with worse survival with regorafenib (HR, 1.88; P = .016) and nitrosoureas (HR, 1.97; P = .020). In the overall cohort, PTEN alteration remained associated with worse survival (HR, 2.04; 95% CI, 1.26-3.30; P = .0039), independently of MGMT promoter methylation. Conclusions PTEN alteration is a clinically relevant prognostic biomarker in recurrent IDH-wildtype glioblastoma and warrants prospective validation as a stratification factor.
Reference Key
openalex_W7171458759 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eugenia Cella, Maurizio Polano, Marta Padovan, Elena Maria Marchesani, Alberto Bosio, Luca Bertero, Marta Maccari, Giulia Cerretti, Mario Caccese, Martina Corrà, E. Bennicelli, Matteo Lambertini, Sara Lonardi, Roberta Rudà, Giuseppe Lombardi
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag196
URL
https://doi.org/10.1093/noajnl/vdag196
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.